WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H401156
CAS#: 1346265-80-2
Description: BRN-103 was found to suppress the VEGF-induced phosphorylation of VEGF receptor 2 (VEGR2) and the activations of AKT and eNOS. Taken together, these results suggest that BRN-103 inhibits VEGF-mediated angiogenesis signaling in human endothelial cells.
Hodoodo Cat#: H401156
Name: BRN-103
CAS#: 1346265-80-2
Chemical Formula: C24H25ClN4O
Exact Mass: 420.17
Molecular Weight: 420.935
Elemental Analysis: C, 68.48; H, 5.99; Cl, 8.42; N, 13.31; O, 3.80
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: BRN103; BRN103; BRN 103
IUPAC/Chemical Name: 2-((1-benzylpiperidin-4-yl)amino)-N-(3-chlorophenyl)nicotinamide
InChi Key: FJLKVQYKXSXIPA-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H25ClN4O/c25-19-8-4-9-21(16-19)28-24(30)22-10-5-13-26-23(22)27-20-11-14-29(15-12-20)17-18-6-2-1-3-7-18/h1-10,13,16,20H,11-12,14-15,17H2,(H,26,27)(H,28,30)
SMILES Code: O=C(NC1=CC=CC(Cl)=C1)C2=C(NC3CCN(CC4=CC=CC=C4)CC3)N=CC=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 420.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Choi HE, Yoo MS, Choi JH, Lee JY, Kim JH, Kim JH, Lee JK, Kim GI, Park Y, Chi YH, Paik SH, Lee JH, Lee KT. BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6236-41. doi: 10.1016/j.bmcl.2011.09.022. Epub 2011 Sep 13. PubMed PMID: 21963305.